ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

Cancer Rates May Rise 50% By 2020, IARC Says

April 18, 2003

Budget Projections for 1978 Offer Clues On Research NCI Hopes To Fund

June 18, 1976

The NLST at a Glance

August 2, 2013

ASCO Releases Guideline On Larynx Preservation

July 28, 2006

Lilly Begins Phase III Trial Of Alimta In Extensive SCLC

October 27, 2006

Kidney Cancer Group Seeks Proposals; AACR Offers Award

November 17, 1995